Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?
- PMID: 16531519
- PMCID: PMC1856175
- DOI: 10.1136/gut.2005.078055
Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?
Abstract
Immunosuppressive drugs have become a mainstay of therapy for the inflammatory bowel diseases. Although robust evidence exists in support of the use of these drugs in Crohn's disease, a close evaluation of the available data in ulcerative colitis reveals a much weaker evidence base. In particular, randomised controlled trials of azathioprine, the most commonly used immunosuppressive agent, do not provide rich evidence of efficacy whereas observational cohorts suggest this agent is effective, particularly in patients with relapsing disease who require corticosteroids. Ciclosporin is also effective in the most refractory cases but its efficacy needs to be carefully weighed against the possibility of rare but life threatening complications. Although the evidence base in support of immunosuppressive drugs in ulcerative colitis is not as strong as in Crohn's disease, these agents clearly have a role in the treatment of this disease.
Comment in
-
Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease.Gut. 2006 Oct;55(10):1525-6. Gut. 2006. PMID: 16966711 Free PMC article. No abstract available.
Similar articles
-
Current status of drug therapy for inflammatory bowel disease.Compr Ther. 1985 Dec;11(12):14-9. Compr Ther. 1985. PMID: 2866866 Review.
-
[Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].Wien Klin Wochenschr. 1998 Sep 4;110(16):579-84. Wien Klin Wochenschr. 1998. PMID: 9782579 German.
-
Immunosuppressive therapy of inflammatory bowel disease: a historical perspective.Gastroenterologist. 1995 Jun;3(2):141-52. Gastroenterologist. 1995. PMID: 7640945 Review.
-
[Chronic inflammatory bowel diseases. Immunosuppressive drugs--good alternatives to steroids].MMW Fortschr Med. 2001 Jul 5;143(26-27):54-6. MMW Fortschr Med. 2001. PMID: 11481920 German. No abstract available.
-
Treatment of ulcerative colitis.Hepatogastroenterology. 2000 Jan-Feb;47(31):83-9. Hepatogastroenterology. 2000. PMID: 10690588 Review.
Cited by
-
An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis.Nat Biomed Eng. 2024 Oct;8(10):1243-1265. doi: 10.1038/s41551-023-01136-9. Epub 2023 Dec 4. Nat Biomed Eng. 2024. PMID: 38049469
-
Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis.J Gastroenterol. 2010 Nov;45(11):1129-37. doi: 10.1007/s00535-010-0273-x. Epub 2010 Jul 8. J Gastroenterol. 2010. PMID: 20614157
-
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):833-42. doi: 10.1080/17425255.2016.1181171. Epub 2016 May 12. Expert Opin Drug Metab Toxicol. 2016. PMID: 27096357 Free PMC article. Review.
-
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.J Gastroenterol. 2011 Feb;46(2):129-37. doi: 10.1007/s00535-010-0352-z. Epub 2010 Dec 4. J Gastroenterol. 2011. PMID: 21132334 Review.
-
Recent advances in the therapeutics and modes of action of a range of agents used to treat ulcerative colitis and related inflammatory conditions.Inflammopharmacology. 2025 Aug 15. doi: 10.1007/s10787-025-01906-8. Online ahead of print. Inflammopharmacology. 2025. PMID: 40815427 Review.
References
-
- Bean R H P. The treatment of chronic ulcerative colitis with 6‐mercaptopurine. Med J Aust 19622592–593. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical